retatrutide mechanism triple agonist glp-1 gip glucagon What Is Retatrutide? The Peptide Explained retatrutide triple agonist glp-1 gip
Description
Fhrmann ER, Adkins L, Loader CJ, et al
Others hit a wall at 8%
Investigating the same primary endpoint, TRANSCEND-T2D-2 (NCT06260722) will compare retatrutide to semaglutide in people with inadequately controlled T2D (treated with oral glucose-lowering treatments) over 26 months
[DOI] [PubMed] [Google Scholar] 61.Trevaskis JL, Wittmer C, Athanacio J, Griffin PS, Parkes DG, Roth JD
Adv Healthc Mater
